HPV vaccine and screening brought to women who need it most

NCT ID NCT06414057

Recruiting now Prevention Sponsor: University of Edinburgh Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study aims to make cervical cancer prevention easier for women who often miss out on routine care, such as those experiencing homelessness, substance use, or incarceration. Researchers will offer the HPV vaccine (Gardasil-9) and a self-swab test during regular sexual health clinic visits. They will track how many women accept the offer and complete the vaccine series, and gather feedback to design better services.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Gardasil-9 (HPV vaccine)
What this could lead to: If successful, this could show that offering HPV vaccines during routine sexual health visits is a practical way to reach and protect women who often miss standard screening and vaccination.
What could go wrong: This is a small, early feasibility study (500 participants) focused on uptake and attitudes, not on directly preventing cancer. Results may not apply to other regions or populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HUMAN PAPILLOMA VIRUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

human papilloma virus infection cervical cancer prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HUMAN PAPILLOMA VIRUS

Contacts and locations

Locations

NHS Lothian
RECRUITING

Edinburgh, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.